# Viridian Therapeutics, Inc. (VRDN)

> Source: Nexqual · https://nexqual.com/VRDN · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Viridian Therapeutics, Inc. (VRDN), nexqual.com/VRDN" · informational, not investment advice.

**Price:** USD 24.8 (+2.18% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 24.27 · day 24.23–25.32 · 52w 13.18–34.29 · market cap $2.81B · NCM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $71.1M, net income -$387M (-544.1% margin), free cash flow -$335M (SEC filings).
- Analysts: Buy (mean 1.82 on a 1–5 scale) (17 analysts), mean target USD 36.2 (range 22–50).
- Total return with dividends: 1Y +2.6% vs S&P 500 +14.8%; 5Y +37.0% vs S&P 500 +79.1%.
- Next earnings: 2026-11-04, EPS estimate USD -1.02, revenue estimate $4.7M. All companies reporting that day: https://nexqual.com/earnings/2026-11-04
- Dividend: VRDN paid no cash dividend in the last five years.
- Short interest: 16.47% of float (as of 2026-10-15), 8.4 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $3.0M | $1.8M | $314K | $302K | $70.8M | $71.1M |
| Operating income | -$79.7M | -$134M | -$254M | -$299M | -$363M | -$405M |
| Net income | -$79.4M | -$130M | -$238M | -$270M | -$343M | -$387M |
| EPS (diluted) | -$6.66 | -$4.05 | -$5.31 | — | — | — |
| Free cash flow | -$54.9M | -$94.6M | -$185M | -$233M | -$277M | -$335M |
| Operating margin | -2690.8% | -7579.2% | -81035.0% | -99018.2% | -512.9% | -569.7% |
| Net margin | -2680.2% | -7329.2% | -75711.5% | -89387.1% | -483.6% | -544.1% |
| Revenue growth | +182.2% | -40.2% | -82.3% | -3.8% | +23359.9% | — |
| Cash + short-term investments | $197M | $425M | $477M | $718M | $875M | — |
| Total debt | $0K | $4.6M | $20.2M | $20.6M | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 39.5x · EV/Sales 29.1x · P/B 4.2x · FCF yield -11.92% · Earnings yield -13.77% · Net cash $739M · EV $2.07B

## Analysts
Consensus Buy (mean 1.82 on a 1–5 scale), 17 analysts; mean target USD 36.2 (low 22, high 50).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-22 | RBC Capital | Target raised | Outperform | $36 → $38 |
| 2026-08-07 | RBC Capital | Target raised | Outperform | $35 → $36 |
| 2026-08-07 | Truist Securities | Target raised | Buy | $38 → $39 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +2.6% | +37.0% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +2.6% | +6.5% |
| Volatility (annualized) | 74.5% | 66.1% |
| Max drawdown | -60.6% (Jan 2026→Apr 2026) | -69.1% (Jan 2023→Oct 2023) |

## Dividends
VRDN paid no cash dividend in the last five years.

## Short interest
18,002,311 shares sold short, 16.47% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 19,465,251 shares (-7.5%). Days to cover: 8.4 (short shares ÷ average daily volume).

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · IOVA (Iovance Biotherapeutics, Inc.) USD 9.56 -35.45% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/VRDN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-1.02 | $-0.93 | −$0.09 | $4.7M | 12 |
| Next quarter (ends 2026-12-31) | $-0.95 | $-0.96 | +$0.02 | $19.2M | 12 |
| Current fiscal year (ends 2026-12-31) | $-3.92 | $-3.80 | −$0.12 | $24.3M | 13 |
| Next fiscal year (ends 2027-12-31) | $-2.71 | $-2.63 | −$0.08 | $237.8M | 13 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$1.05 | −$1.03 | Miss −1.9% | — |
| — | Quarter ended Mar 31, 2026 | −$0.90 | −$1.08 | Beat +16.7% | — |
| — | Quarter ended Dec 31, 2025 | −$1.08 | −$1.00 | Miss −8.0% | — |
| — | Quarter ended Sep 30, 2025 | −$0.34 | −$0.94 | Beat +63.8% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).